Tizanidine Tablet
Product Images NDC 72789-326

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 72789-326). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (72789325)

Label for Tizanidine 4 mg tablets by PD-Rx Pharmaceuticals, Inc., containing 30 tablets. The label includes storage instructions, a caution that these tablets are not interchangeable with Tizanidine capsules, packaging details with NDC 72789-325-30, and manufacturer information from Alkaloda Chemical Company Zrt., Hungary.*

FDA Label Image

Image (72789326)

Label for Tizanidine 2 mg oral tablets by PD-Rx Pharmaceuticals, Inc. The label states a 30 tablet count and includes a caution that Tizanidine Tablets are not interchangeable with Tizanidine Capsules. It provides storage instructions, a barcode, NDC 72789-326-30, and manufacturer information for Alkalodia Chemical Company in Hungary. The label also displays a lot number and expiration date.*

FDA Label Image

Tizanidine-1 (Tizanidine 1)

Chemical structure diagram of the active ingredient Tizanidine, showing its molecular components including chlorine, sulfur, nitrogen atoms, and an attached hydrochloride group.*

FDA Label Image

Tizanidine-2 (Tizanidine 2)

A line graph showing plasma Tizanidine concentration (ng/mL) over time (hours) after dosing. The graph compares 4 mg Tizanidine tablets and capsules taken with and without food. Concentrations peak within 2-3 hours and decline thereafter, with different curves for each dosing condition.*

FDA Label Image

Tizanidine-3 (Tizanidine 3)

A line graph depicting improvement in Ashworth Score over hours post-dose, comparing 16 mg tizanidine, 8 mg tizanidine, and placebo groups. The y-axis shows improvement scores and the x-axis denotes time in hours up to 6 hours post-dose, with error bars shown for each data point.*

FDA Label Image

Tizanidine-4 (Tizanidine 4)

A line chart comparing improvement in Ashworth Score over time between tizanidine (mean dose 28.8 mg) and placebo groups. The x-axis represents three time points: end of titration (Week 3), end of maintenance (Week 17), and endpoint (last observation carried forward). The y-axis shows improvement score ranging from -6 to 2. Tizanidine shows greater improvement (lower score) than placebo at all measured points, with error bars indicating variability.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.